Aethlon Medical to Present at The Salk Institute
12 Marzo 2010 - 2:00PM
PR Newswire (US)
SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc.
(OTC Bulletin Board: AEMD), the pioneer in developing therapeutic
filtration devices to address infectious disease and cancer,
announced that Richard H. Tullis, Ph.D., the company's Chief
Science Officer, will present at the French Biotech Tour held at
The Salk Institute in La Jolla, California, on March 15, 2010.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)
The French Biotech Tour is a showcase of the most innovative
technologies and solutions developed by Californian and French
biotech companies to tackle infectious diseases and to improve
patients' quality of life. About Aethlon Medical Aethlon Medical,
Inc. creates diagnostic and therapeutic device solutions for
infectious disease and cancer. Our lead product, the
Hemopurifier ® is the first-in-class medical device to
selectively capture circulating viruses and immunosuppressive
proteins prior to cell and organ infection. Human studies have
documented the ability of our Hemopurifier ® to reduce viral
load in patients infected with Hepatitis-C virus (HCV) and the
Human Immunodeficiency Virus (HIV). Our primary clinical and
commercialization focus is to establish the Hemopurifier ® as
an adjunct therapy to enhance and prolong the benefit of
traditional infectious disease drug regimens. The
Hemopurifier ® is also a broad-spectrum treatment candidate
against drug resistant bioterror and pandemic threats. Third party
research institutes have verified the capability of the device to
capture Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa
Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus,
2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918
Virus, and Monkeypox Virus, which serves as a model for human
Smallpox infection. Our wholly owned subsidiary, Exosome Sciences,
Inc. (ESI) was formed in October of 2009 to leverage attributes of
the Hemopurifier ® in the emerging exosome research field. ESI
seeks to inhibit the immune cell destruction caused by exosomes
secreted by solid tumors, lymphomas, and leukemia. At present, the
capture of immunosuppressive exosomes secreted from ovarian cancer
tumors has been demonstrated invitro. The preservation of
anti-cancer immune cells would likely improve patient
responsiveness to established treatment options, including
immunotherapy and chemotherapy. ESI is also analyzing
exosome-related opportunities to improve early cancer detection and
post-surgery surveillance of tumor growth, as well as approaches to
harvest exosomes for research purposes and potential reintroduction
into patients afflicted with autoimmune conditions such as
Rheumatoid Arthritis and Lupus. Additional information regarding
Aethlon Medical and Exosome Sciences can be accessed online at
http://www.aethlonmedical.com/. Certain of the statements herein
may be forward-looking and involve risks and uncertainties. Such
forward-looking statements involve assumptions, known and unknown
risks, uncertainties and other factors which may cause the actual
results, performance or achievements of Aethlon Medical, Inc. to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such potential risks and uncertainties include, without
limitation, the capability of the Hemopurifier ® to reduce
viral loads and other disease conditions or to identify disease
conditions such as cancer, including the ability to capture
exosomes and the impact that potential ability may have on disease
conditions, the Company's ability to raise capital when needed, the
Company's ability to complete the development of its planned
products, the ability of the Company to obtain FDA and other
regulatory approvals permitting the sale of its products, the
Company's ability to manufacture its products and provide its
services, the impact of government regulations, patent protection
on the Company's proprietary technology, product liability
exposure, uncertainty of market acceptance, competition,
technological change, and other risk factors. In such instances,
actual results could differ materially as a result of a variety of
factors, including the risks associated with the effect of changing
economic conditions and other risk factors detailed in the
Company's Securities and Exchange Commission filings. Contacts: Jim
Joyce Chairman, CEO 858.459.7800 x301 jj@aethlonmedical.com John P.
Salvador Director of Corporate Communications 858.459.7800 x307
jps@aethlonmedical.com DATASOURCE: Aethlon Medical, Inc. CONTACT:
Jim Joyce, Chairman, CEO, +1-858-459-7800, ext.
301,jj@aethlonmedical.com, or John P. Salvador, Director of
CorporateCommunications, +1-858-459-7800, ext. 307,
jps@aethlonmedical.com Web Site: http://www.aethlonmedical.com/
Copyright
Grafico Azioni Aem Spa (LSE:AEM)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Aem Spa (LSE:AEM)
Storico
Da Set 2023 a Set 2024